B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study

Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment

(2010) E. M. Vital et al.   ARTHRITIS AND RHEUMATISM

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

B cells in the pathogenesis and treatment of rheumatoid arthritis

(2010) Bethany Marston et al.   CURRENT OPINION IN RHEUMATOLOGY

Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers

(2010) Thomas Dörner et al.   PHARMACOLOGY & THERAPEUTICS

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort

(2009) Jacques-Eric Gottenberg et al.   ARTHRITIS RESEARCH & THERAPY

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES